FDAnews
www.fdanews.com/articles/195840-sanofi-indicted-in-france-over-epilepsy-drug-depakine

Sanofi Indicted in France over Epilepsy Drug Depakine

February 11, 2020

Sanofi Aventis France was indicted as part of a criminal investigation relating to birth defects and slow neurological development linked to its epilepsy treatment Depakine (valproic acid).

The investigation began after a French inspection agency criticized the company’s response to the risks of taking the drug during pregnancy.

The FDA warned against the use of valproate anti-seizure products, including Depakine and its generics, in pregnant women in 2013 due to decreased IQ scores in exposed children.

Sanofi said that the indictment will allow the company to “demonstrate it has respected its duty to inform and show transparency.”

View today's stories